HLX43 DOSE 1 Clinical Trials
6 recruitingDrug
Phase 26
Showing 1–6 of 6 trials
Recruiting
Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Carcinoma of Head and/or Neck
Shanghai Henlius Biotech167 enrolled2 locationsNCT06857279
Recruiting
Phase 2
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
Shanghai Henlius Biotech60 enrolled1 locationNCT07269782
Recruiting
Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
Esophageal Cancer
Shanghai Henlius Biotech72 enrolled1 locationNCT06769113
Recruiting
Phase 2
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
Nasopharyngeal Carcinoma (NPC)
Shanghai Henlius Biotech70 enrolled15 locationsNCT06839066
Recruiting
Phase 2
Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Henlius Biotech60 enrolled1 locationNCT07115485
Recruiting
Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
Carcinoma, Hepatocellular
Shanghai Henlius Biotech90 enrolled1 locationNCT06742892